Following on from its successful validation in blood glucose testing, Universal Biosensors (UBI) adapted its electrochemical cell to measure Prothrombin Time (PT/INR), a test used to monitor the effect of the anticoagulant therapy warfarin.
Point-of-care coagulation testing takes place in three broad settings:
- Alternative Site Testing, including doctors’ offices, clinics, pharmacies, etc.
- Patient self-testing in the home
In 2014 Siemens Healthcare launched the UBI developed Xprecia Stride™ Coagulation Analyzer and Test Strip to provide a quick, convenient and accurate method for medical practitioners to conduct the test in the hospital and alternative site testing facilities.
The test is used to maintain patients on a safe and effective dose of warfarin. If patients are taking too much warfarin they are at risk of serious bleeding events and if too little they are at risk of thrombosis.
The prothrombin time test allows physicians to adjust patient doses for diet and lifestyle changes. It is estimated that over 10 million people are taking warfarin and more than 200 million PT-INR tests are conducted each year worldwide.
The point-of-care coagulation monitoring market is estimated to be worth approximately US$1 billion globally with point-of-care PT-INR testing making up over 65% of this market.
Primary care, urgent care, and hospitals demand fast, reliable PT/INR testing for oral anticoagulation therapy (OAT). That’s why UBI has acquired the global distribution rights from Siemens for the Xprecia Stride™ Coagulation Analyzer, a truly handheld device that tests PT/INR with lab accuracy.
Future and market potential.